Amyloid-targeted monoclonal antibodies are the first disease-modifying therapies (DMTs) approved for Alzhemier’s disease (AD). Aducanumab received accelerated approval by the FDA but was not fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results